Physician profile
Roopal Bhatt
NPI 1649253279
$4,323.64
in general payments reported to CMS, 2019-2025
25 companies · $1,142 in 2025
The $1,142 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $739 · 2020: $106 · 2021: $42.10 · 2022: $478 · 2023: $620 · 2024: $1,197 · 2025: $1,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,855 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,855.10 |
| Education | $103.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $991.50 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $447.42 | 2022-2025 | Tremfya |
| Leo Pharma INC. | $437.77 | 2022-2025 | Adbry |
| Amgen INC. | $318.50 | 2019-2025 | Otezla, Otezla |
| Ucb, INC. | $276.61 | 2022-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $259.20 | 2020-2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $217.46 | 2019-2025 | |
| Pfizer INC. | $172.66 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $160.30 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $149.12 | 2022-2025 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $133.05 | 2019-2025 | Jublia, Arazlo, Duobrii |
| Incyte Corporation | $127.68 | 2021-2025 | Opzelura |
| Journey Medical Corporation | $113.64 | 2022 | |
| Lilly USA, LLC | $99.16 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Botanix Sb INC | $86.58 | 2025 | Sofdra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $69.20 | 2019 | |
| Mayne Pharma Commercial LLC | $59.84 | 2019 | |
| Aclaris Therapeutics, INC. | $43.85 | 2019 | |
| Dermavant Sciences, INC. | $32.65 | 2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $31.84 | 2023-2025 | Winlevi, Absorica Ld |
| Encore Dermatology INC. | $27.82 | 2019-2020 | |
| Genzyme Corporation | $24.30 | 2019 | |
| Merz North America, INC. | $15.85 | 2019 | |
| Arcutis Biotherapeutics, INC. | $14.85 | 2023 | |
| Epi Health, LLC | $12.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roopal Bhatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.